Among patients experiencing PD, the median plasma levels of stromal derived factor-1 and vascular endothelial growth factor-A were significantly higher compared with the baseline (P=0.01; P=0.011). Changes in levels of selected CAFs were associated with response/resistance to pazopanib in mRCC patients.